Fabien B. Vincent

Research Fellow; Rheumatology Research Group, Centre for Inflammatory Diseases, Monash University

Dr. Vincent is a physician-scientist currently employed as a research fellow in the rheumatology group, centre for inflammatory diseases at Monash University.

He completed his medical training, including advanced training in rheumatology, at the University Hospital Centre of Caen and Paris in France between 1999 and 2010. He completed his PhD in immunology at Monash University in Melbourne between 2012 and 2018.

Dr. Vincent's specialization is in rheumatology with a focus on autoimmunity, specifically molecular and B cell immunology, and biomarker development in systemic lupus erythematosus. Dr. Vincent has a strong interest in Indigenous Australian health research.

Experience

  • 2016–present
    Research Fellow, Rheumatology Research Group, Centre for Inflammatory Diseases, Monash University
  • 1999–2010
    Medical Training, University Hospital Center (CHU) of Caen and Paris, France

Education

  • 2018 
    Monash University, Melbourne, Australia, PhD in Immunology
  • 2011 
    University of Paris-Sud XI, France, Master in Sciences – Immunology, with high honours
  • 2010 
    University of Medicine, Caen, France, M.D., Rheumatology board certified
  • 2010 
    University of Medicine, Paris and Lille, France, Degree in Polyarthritis and Autoimmune Disease
  • 2010 
    University of Medicine, Caen, France, Master in Clinical Research, with high honours
  • 2009 
    University of Medicine, Nantes, France, Degree in interventional rheumatology
  • 2002 
    University of Medicine, Caen, France, Degree in Cytopathology and Immunopathology
  • 1999 
    Dumont D’Urville High School, Caen, France, High school degree in science, with honors

Publications

  • 2020
    Vincent FB, Lang T. (2020) Measuring MIF in Biological Fluids. In: Harris J., Morand E. (eds) Macrophage Migration Inhibitory Factor. , Methods in Molecular Biology, vol 2080. Humana, New York, NY
  • 2019
    Nim HT†, Connelly K†, Vincent FB, Petitjean F, Hoi A, Koelmeyer R, Boyd E, Morand EF. Novel methods of incorporating time in longitudinal multivariate analysis reveals hidden associations with disease activity in systemic lupus erythematosus. , Front Immunol 2019; 10:1649
  • 2019
    Vincent FB, Lang T, Kandane-Rathnayake R, Downie-Doyle S, Morand EF and Rischmueller M. Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren’s syndrome. , Joint Bone Spine 2019; 86:393-5
  • 2019
    Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F and Morand EF. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. , Clin Transl Immunology 2019; 8:e01047
  • 2019
    Lin E†, Vincent FB†, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Morand EF, Lang T†, Harris J†. Analysis of serum interleukin (IL)-1alpha, IL-1beta and IL-18 in patients with systemic sclerosis. , Clin Transl Immunology 2019; 8:e1045
  • 2019
    Vincent FB†, Nim H†, Thomas JPW, Morand EF† and Harris J†. Effect of storage duration on cytokine stability in human serum and plasma. , Cytokine 2019; 113:453-7
  • 2019
    Vincent FB, Bubicich M, Downie-Doyle S, Mackay F, Morand EF and Rischmueller M. Serum soluble Fas and Fas ligand (FasL) in Primary Sjögren’s Syndrome. , Clin Exp Rheumatol 2019; 37 (Suppl 118):254-6
  • 2018
    Vincent FB†, Lin E†, Sahhar J, Ngian GS, Kandane-Rathnayake R, Mende R, Hoi AY, Morand EF, Lang T†, Harris J†. Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis., Clin Transl Immunology 2018; 7:e1042
  • 2018
    Vincent FB, Kandane-Rathnayake R, Hoi AY, Slavin L, Godsell JD, Kitching AR, Harris J, Nelson CL, Jenkins AJ, Chrysostomou A, Hibbs ML, Kerr PG, Rischmueller M, Mackay F and Morand EF. Urinary B Cell-Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Systemic Lupus Erythematosus. , Lupus 2018; 27:2029-40
  • 2018
    Vincent FB, Slavin L, Hoi AY, Kitching AR, Mackay F, Harris J, Kandane-Rathnayake R† and Morand EF†. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. , Lupus Sci Med 2018; 5:e000277
  • 2018
    Mende R†, Vincent FB†, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, Hoi A, Morand EF, Harris J† and Lang T†. Analysis of Serum Interleukin (IL)-1b and IL-18 in Systemic Lupus Erythematosus. , Front Immunol 2018; 9:1250
  • 2016
    Vincent FB†, Pavy S†, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X† and Miceli-Richard C†. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. , Joint Bone Spine 2016; 83:595-7
  • 2016
    Michel M, Vincent FB, Rio S, Leon N, Marcelli C. Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs. , Joint Bone Spine 2016; 83:237-8
  • 2016
    Saulep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM, Tam C, Mackay F. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. , Leukemia 2016; 30:163-72
  • 2015
    Rio S, Vincent FB, Michel M, Cesini J, Marcelli C. Tumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre study. , Joint Bone Spine 2015; 82:377-8
  • 2015
    Fairfax KA, Tsantikos E, Figgett WA, Vincent FB, Quah PS, LePage M, Hibbs ML, Mackay F. BAFF-driven autoimmunity requires CD19 expression. , J Autoimmun 2015; 62:1-10
  • 2014
    Figgett WA, Vincent FB, Saulep-Easton D and Mackay F. Roles of ligands from the TNF superfamily in B cell development, function, and regulation. , Semin Immunol 2014; 26:191-202
  • 2014
    Saulep-Easton D, Vincent FB, Le Page M, Wei A, Ting SB, Croce CM, Tam C and Mackay F. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia., Leukemia 2014; 28:2005-15
  • 2014
    Giles ML†, Vincent FB†, Volkenstein S, Shefin SM, Silva A, Fredrick F; Young Physician Leadership Group 2013. What has the Young Physician Leaders Programme achieved? , Lancet 2014; 384:26-7
  • 2014
    Vincent FB, Morand EF, Schneider P and Mackay F. The BAFF/APRIL system in SLE pathogenesis., Nat Rev Rheumatol 2014; 10:365-73
  • 2013
    Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA and Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. , Cytokine Growth Factor Rev 2013; 24:203-15
  • 2013
    Vincent FB, Bourke P, Morand EF, Mackay F and Bossingham D. Focus on systemic lupus erythematosus in Indigenous Australians: toward a better understanding of autoimmune diseases. , Intern Med J 2013; 43:227-34
  • 2013
    Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X and Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. , Ann Rheum Dis 2013; 72:165-78
  • 2013
    Vincent FB, Northcott M, Hoi A, Mackay F and Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. , Arthritis Res Ther 2013; 15:R97
  • 2013
    Murielle M, Henri P, Vincent FB, Leon N and Marcelli C. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. , Joint Bone Spine 2013; 80:660-3
  • 2013
    Figgett WA, Fairfax K, Vincent FB, Le Page MA, Katik I, Deliyanti D, Quah PS, Verma P, Grumont R, Gerondakis S, Hertzog P, O’Reilly LA, Strasser A and Mackay F. The TACI Receptor Regulates T-Cell-Independent Marginal Zone B Cell Responses through Innate Activation-Induced Cell Death. , Immunity 2013; 39:1-11
  • 2013
    Vincent FB, Northcott M, Hoi A, Mackay F and Morand EF. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. , Lupus 2013; 22:873-84
  • 2012
    Vincent FB, Morand EF and Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus., Immunol Cell Biol 2012; 90:293-303

Grants and Contracts

  • 2020
    Identification of molecular signatures in Indigenous Australians with systemic lupus erythematosus
    Role:
    CIA
    Funding Source:
    AFA/ARA Heald Fellowship funded by Arthritis Australia
  • 2019
    Identification of molecular signatures in Indigenous Australians with systemic lupus erythematosus
    Role:
    CIA
    Funding Source:
    Janssen-Cilag Pty Ltd Medical Grant
  • 2019
    Identification of molecular signatures in Indigenous Australians with systemic lupus erythematosus
    Role:
    CIA
    Funding Source:
    Rebecca L. Cooper Medical Research Foundation

Professional Memberships

  • Société Française de Rhumatologie (SFR)
  • Australian Rheumatology Association (ARA)

Research Areas

  • Rheumatology And Arthritis (110322)
  • Immunology (1107)
  • Applied Immunology (Incl. Antibody Engineering, Xenotransplantation And T Cell Therapies) (110702)
  • Autoimmunity (110703)
  • Sports Medicine (110604)
  • Innate Immunity (110707)